Development of therapeutic strategy for neurodegenerative diseases by intranasal administration of antimiR.
| Project/Area Number |
16K08556
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Teikyo University |
|---|
Principal Investigator |
Aoyama Koji 帝京大学, 医学部, 教授 (00420943)
|
|---|
| Project Period (FY) |
2016-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | グルタチオン / microRNA / 神経変性疾患 / グルタミン酸トランスポーター / glutathione / 薬理学 / 神経科学 |
|---|
| Outline of Final Research Achievements |
The aim of this study was to clarify whether intranasal administration of an inhibitor (antimiR) to microRNA-96-5p, which suppresses neuronal glutathione (GSH) production, can increase GSH levels against neurodegeneration due to oxidative stress in the mouse brain. Although the neuroprotective effect is still inconclusive under oxidative stress, a high-dose intranasal administration of antimiR to microRNA-96-5p confirmed the central migration and increased neuronal GSH levels in the hippocampus. Additional drug delivery strategy to the intranasal administration would be needed for both enhancing the efficacy and reducing the dose of antimiR in vivo.
|
| Academic Significance and Societal Importance of the Research Achievements |
生体においては多くの物質が血液脳関門を通過しにくいため、静脈内投与以外の投与法による薬物送達の可能性を探ることが重要である。近年、経鼻投与法による薬物の脳内への移行性が示唆されており、血液脳関門に影響されない新たな薬物投与法としての可能性が期待されている。本研究結果から、経鼻投与法は脳内へantimiRを移行させ神経細胞内GSH量を増加させたことから将来的に神経変性疾患治療薬への応用が期待される。
|
Report
(5 results)
Research Products
(9 results)
